Background: Sex steroid hormones have been proposed to play a role in the development of non-
Introduction
Non-epithelial ovarian cancers (NEOC) account for approximately 10% of all ovarian tumors and about 7% of the invasive ones (1) . They are divided into two major distinct subtypes, sex cord-stromal tumors (SCST) and germ cell tumors (GCT) (1) (2) (3) . SCST occur in women of all ages but increase in frequency during the 4th and 5th decades of age and have a median age at diagnosis of 52 years (4) (5) (6) . In contrast, GCT occur predominantly in young women with the peak incidence around age 18 and are rarely observed after age 30 (7) . The incidence rates of the two subtypes of NEOC also differ by race: SCST are twice as frequent in women of European and American background than in women from Asian descent (4), while GCT are more frequent in Asian women (8;9) .
Because of the low incidence of NEOC, very few studies have investigated risk factors for their development. So far, only 6 studies, 5 of which included between 10 and 72 cases of SCST or GCT, have reported on the association of these tumors with traditional reproductive risk factors, such as parity, oral contraceptive use, ages at the first and last births, and time since last birth (1;10-14) . Although the results from these studies are not entirely consistent, parous women appear to be at reduced risk of both SCST and GCT (1;10;12), but, there is some indication that the effect of other reproductive factors (1;11;12;15) , particularly age at last birth (11;12) may differ in the two subtypes. It has also been suggested that exposure to high estrogens in utero may be associated with NEOC in the offspring (16;17) and, possibly, also in the mother (11) .
The association of NEOC with concentrations of sex steroid hormones during the last pregnancy preceding the index diagnosis was explored in a case-control study, nested within the large, nation-wide Finnish Maternity Cohort (FMC). Early pregnancy (6-21 gestational weeks) concentrations of testosterone, androstenedione, 17-OH-progesterone (the precursor hormone for ovarian and adrenal synthesis of androgens (18;19)), progesterone, estradiol and sex hormone binding globulin (SHBG) were measured. To our knowledge, this is the first epidemiological 8 5.0 ng/mL for estradiol, showed inter-run coefficients of variation (CV) of 14.6%, 5.3%, 5.0%, 5.0% and 8.3%, respectively. Inter-and intra-run CV based on the blinded pool of quality controls were 3.6% and 7.8% for testosterone, 4.0% and 8.3% for androstenedione, 5.4% and 8.1% for 17-OH-progesterone, 3.5% and 7.0% for progesterone, and 5.5% and 6.3% for estradiol. SHBG was quantified with solid-phase competitive chemiluminescence assays on Immulite 2000 Siemens analyzer. The inter-run CV based on laboratory quality controls with concentrations of 41 nmol/L was 1.5%. Due to low sample volume, SHBG measurements were possible only 25 SCST cases and 43 matched controls, and 13 GCT cases and 27 matched controls. Bioavailable fractions of testosterone and estradiol concentrations were calculated by mass action models based on concentrations of total hormones in blood and their affinity constants for albumin and SHBG (28) .
No outliers, defined as concentrations exceeding 3 times the interquartile range, for any of the hormones were identified.
Statistical analysis
Prior to analysis, all original hormone values were log 2 -transformed to normalize their distributions. Hormone concentrations varied linearly with gestational age (Figure 1 ) and all statistical analyses were adjusted for gestational age.
Pearson partial correlation coefficients were used to relate hormone concentrations to specific characteristics of interest [e.g., maternal age at sampling (last birth)]. Mixed effect models were used to compare mean hormone concentrations in cases and controls. The conditional logistic regression models (appropriate for the individually matched design) were used to compare differences between cases and controls and to calculate odds ratios (OR) and corresponding 95% confidence intervals (CI) for SCST and GCT. For the hormonal variables, ORs were calculated for a unit change of log 2 -transformed concentrations, which corresponds to a doubling of the concentrations. To ensure that study results were not influenced by the presence of yet undiagnosed, but hormonally active tumor, sensitivity analyses excluding women diagnosed within 2, 4 and 6 years after blood donation were conducted. For subjects with SHBG measurements, bioavailable 9 fractions of testosterone and estradiol were also related to risk. Further subgroup analyses by ages at sampling (< 30 vs. ≥ 30 years) and cancer diagnosis (below and above 40 years), limited to multiparous women, to those who donated an eligible sample during the last pregnancy preceding index date, or with borderline tumors for SCST were also performed. Tests of homogeneity between the odds ratios in different subgroups were based on Chi-square statistics, calculated as the deviations of logistic regression coefficients observed in each of the subgroups, relative to the overall regression coefficient (29) . The effect of potential confounders (e.g. maternal age at first birth, family history of breast/ovarian cancers, maternal smoking, the child's sex, birth length and weight) was evaluated and variables that changed point estimates by more than 5% for two or more hormones were retained in the final models. The effect of adjustment for hormone concentrations included adjustment of testosterone models for androstenedione (and vice versa) and adjustment of androgen and progesterone models for 17-OH-progesterone (and vice versa) was also explored. All tests of statistical significance were two-sided and the ORs were considered significant if the p values were < 0.05.
The study was approved by the ethical committees of the National Institute for Health and Welfare, Finland, University of Umea, Sweden, and German Cancer Research Center, Germany.
Results
SCST and GCT cases and their respective control subjects were comparable in most pregnancy, maternal and child characteristics ( Table 1 ). The median age at diagnosis was 39 years (range: 23.1-50.0) for SCST and 35 years (range: 21.1-51.4) for GCT. The majority of SCST were borderline tumors (33 cases, 80%), whereas most of GCT were invasive cancer (18 cases, 86%).
The vast majority of SCST (85%, 35 cases) were granulosa cell tumors. The lag-time between blood donation and diagnosis was shorter for GCT than for SCST (4.1 vs. 6.8 years, respectively).
Correlations of sex steroids hormones with each other and with gestational age and maternal age at sampling in the all control subjects (N=171) are presented in Table 2 . The strongest correlations were observed between the two androgens (r=0.87) which were also directly correlated with 17-OH-progesterone (r=0.54 and 0.63 for testosterone and androstenedione, respectively). Testosterone, androstenedione and 17-OH-progesterone concentrations were significantly higher in SCST cases than in their controls, but no other significant differences in hormone levels between SCST or GCT cases and their controls were observed (Table 1) . SHBG concentrations were marginally higher in SCST cases than in their controls (189 vs. 162 nmol/L, p = 0.08, with only 25 cases and 43 controls). Correspondingly, in conditional regression analyses (Table 3) doubling of androgen and 17-OH-progesterone concentrations were associated with about 2-fold increase in risk of SCST. Adjustment for maternal age at first birth, family history of breast/ovarian cancers, maternal smoking, and child sex increased risk estimates, with maternal age at first birth having the greatest impact (about 9% increase of androgen and 5% increase for 17-OHprogesterone estimates). The associations remained largely unchanged after excluding women with 2, 4 or 6 years lag-time between blood donation and cancer diagnosis ( Subgroup analyses by ages at sampling and diagnosis indicated somewhat stronger associations in women who were diagnosed before age 40 than after that age, but the heterogeneity tests reached statistical significance only for the effect of doubling of 17-OH-progesterone. In spite of statistical significance, however, these results should be interpreted with some caution as the heterogeneity tests were based on small numbers of subjects and were sensitive to selection of cut- Sex steroids showed were not associated with maternal risk of GCT (Table 4) . SHBG concentrations were associated with higher risk (not statistically significant), however only 13 casecontrol sets were included in this analysis, and the CI were large [OR and 95% CI of 2.01 (0.39-
10.27)]. Analyses excluding case-control sets with lag-time to diagnosis of 2, 4, and 6 years and

Discussion
This is the first prospective study to provide direct epidemiological evidence that elevated blood levels of sex steroid hormones during pregnancy, androgens in particular, may be related to an increased risk of developing SCST. Doubling of testosterone, androstenedione and 17-OHprogesterone (the precursor hormone for androgen synthesis) during the early part of the last pregnancy leading to child birth and preceding cancer diagnosis was associated with an approximately 2-fold greater risk of SCST. In contrast, none of the studied steroid hormones showed any association with risk of GCT.
Changes of sex steroids throughout pregnancy are summarized as below. Concentrations of testosterone are relatively stable throughout pregnancy, as demonstrated by longitudinal studies (30;31) . One longitudinal study (31) shows that total testosterone levels remain relatively stable till the third trimester and increase 62% from 6th to 34th week of gestation, and the other longitudinal study (30) reports that total testosterone increases approximately 29% from 5th to 40th week of gestation. The free testosterone levels are within the range of non-pregnant women and gradually increase during the latter parts of pregnancy (31;32). Androstenedione levels only slightly increase throughout pregnancy in the longitudinal studies (30;31;33) . 17-OH-progesterone levels reach their peak during the 5-6th week of pregnancy and then gradually decrease thereafter, but increase again during the latter parts of pregnancy (30;34) . There are small variations in progesterone levels, similar to pre-pregnancy state (luteal phase of the menstrual cycle), from 3rd to 13th week of gestation and, progesterone levels increase significantly thereafter (30;34;35) . Estradiol levels rise steadily from 3rd to 13th week of gestation (by 8th week of gestation its levels are above the range found during menstrual cycle) and then gradually increase thereafter (34) (35) (36) (37) . SHBG levels increase rapidly during the first half of pregnancy (till 25th week of gestation), then remained relatively constant until delivery (30;31). All studied hormones levels at 1 year postpartum drop down to below the first trimester values, similar to the pre-pregnancy state (31;33) . (38) (39) (40) (41) (42) . In particular, testosterone and dehydroepiandrosterone strongly promote carcinogenesis of spontaneous ovarian granulosa cell tumors (the predominant histological subtype in this study) in SWXJ-9 strain mice (38) and continuous administration with testosterone shortly after birth induced theca-cell ovarian tumors (also belonging to SCST) in the rat (39) .
Therefore, it is plausible that androgens are involved in the pathogenesis of SCST in humans.
The elevations in androgens and 17-OH-progesterone in the SCST case subjects are likely to be of maternal origin. Although the placenta produces androstenedione and testosterone from fetal precursors, these are rapidly converted to estrogens due to its potent aromatase capacity (43) . 17- androgens during early pregnancy. Similarly, this assumption is likely generalizable to women with polycystic ovary syndrome (PCOS) as evidence (37;43) has demonstrated that pregnant women with PCOS, having elevated pre-pregnancy androgens, continue to maintain higher androgens also during pregnancy, compared to normal pregnant women with normal androgen levels. Therefore, the observed increase in risk of SCST associated with doubling of testosterone in our study may be applicable also to the effect of elevated androgens / altered maternal androgen metabolism in the non-pregnant state.
The major strength of our study is its prospective design, which largely avoids selection and inverse causation biases which plague studies of a classical case-control design. Case and control subjects were tightly matched for age at sampling (last birth), parity at the index pregnancy, and date of sampling, allowing careful control for these important sources of potential confounding.
SCST develop from the theca and granulosa cells, which are the major site of steroid hormones synthesis in the ovary (4;46), and these tumors are often hormonally active (5;47). To reduce the possibility that the observed associations with risk of SCST were influenced by hormonal secretion by a growing, but still undiagnosed tumour we limited the analyses to women whose samples were donated 2, 4 and 6 years prior to their cancer diagnosis. For testosterone, the more potent androgen, risk estimates remained strong and statistically significant, while those for androstenedione were slightly reduced and became of borderline significance. Thus, it is unlikely that the observed associations in our study were due to reverse causation bias.
The very large overall size of Finnish Maternity Cohort (N ≈ 850,000) made it possible to study the hormonal determinants of non-epithelial ovarian tumors, which are rare forms of cancer, although the very small numbers of cases, particularly for GCT, was insufficient to detect moderate or weak hormone-risk associations. A limitation of our study is that no data on maternal prepregnancy hyperadrogenism / testosterone concentrations were available and the lack of sufficient sample for analyses of SHBG in all subjects. Study samples had been stored at relatively high It is not feasible in the study design to select controls matched to cases on gestational age, even in much larger cohorts and will pose unreasonable, severe restrains on control selection.
Therefore, the only alternative is to adjust for gestational age in the phase of data analysis to minimize the intra-person variability in sex steroids levels during pregnancy. One approach is adjusted for a linear term of gestational age, and the other is calculating residual values by the local linear regression (49) . We adopt the former approach in the manuscript due to the following four reasons. Firstly, concentrations of all studied hormone varied linearly with gestational age ( Figure   1 ). Secondly, the same approach has been extensively used in various epidemiological studies (50) (51) (52) (53) . Thirdly, in fact the former approach provides more straightforward interpretation in comparison with the presentation of residual values by the local linear regression, as the latter approach is required to calculate the difference (residual) between the assay value and the estimated mean hormone value determined for the day of gestation on which the blood sample was donated.
Lastly, results obtained by both approaches give almost identical results. It is also possible that hormones levels adjusted for gestational age could be subject to measurement error. However the intra-person variability in biomarker levels from a single measurement is unlikely to be differential with respect to cases and controls and would most likely lead to an underestimation of the effect estimates, as supported by other studies (54) (55) (56) (57) .
Another relative limitation of the study might be that only a single blood sample was obtained for each pregnant woman. A single measurement for endogenous sex steroids in premenopausal women is suggested to reliably estimate average levels for serum androgen and SHBG over a 1-3 year period (58;59;55;60;61). To our knowledge, so far no study on the reproducibility of a single measurement for endogenous sex steroids in pregnant women has been reported and little is known about the intra-person variability in sex steroids during pregnancy. for SHBG, and 0.25 for estradiol; while in black women were more higher, 0.67 for testosterone, 0.43 for SHBG, and 0.35 for estradiol (63) . Thirdly, correlations between the second and third trimester were 0.78 for estradiol and 0.60 for total estrogen (64) . In addition, strong correlations during successive pregnancies of the same women for estrogen have been reported, e.g., pregnancy estradiol, measured between 8th and 17th of gestational weeks, were strongly correlated in successive pregnancies of the same women (0.78 for total estradiol and 0.73 for free estradiol) (65).
It is plausible to assume that the correlations of hormone levels measured within the same pregnancy is most likely higher than those correlations of hormone levels measured in successive pregnancies.
Taken together, a single measurement for androgens (testosterone in particular) during early pregnancy can reliably represent cumulative exposure to the hormone as strong correlations during the different period of the same pregnancy for testosterone have been reported, e.g., correlations
between the first and second trimester were 0.83 for Caucasian women in Boston and 0.62 for were donated around the first trimester-between the 6th and 21th weeks of gestation, which is likely to be the most relevant period for the exposure to early pregnancy androgens (testosterone in particular), also reflecting pre-pregnancy exposure to the hormone.
A completion of the first full-term pregnancy may induce substantial alternations in a women's hormonal milieu as most studies have shown that in pregnant state, parous women have lower concentrations of a number of hormones, including estrogens and androgens (64;66-69) , compared with nulliparous women. Effects of pregnancy on hormone levels may sustain in the nonpregnant state, e.g., before and after menopause. Although, some studies report that nulliparous women had similar (higher trend, but not statistically significant) androgens (testosterone and androstenedione) levels, in comparison to parous women, both in the pre-menopausal (70;71) and post-menopausal women (72) (73) (74) . Most studies support of reductions in concentrations of sex steroids after the first full-term pregnancy both in the pre-menopausal women for androgens (dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS)) (75),
progesterone (71), and estrogens (free estradiol) (76) and, also in the post-menopausal women for androgens (testosterone) (77), and estrogens (free estradiol (78) and estrone sulfate (79)).
Therefore, the effect of pregnancy on maternal risk of NEOC is most likely to be the result of the cumulative long-term exposure of androgens (testosterone in particular) throughout a woman' life-cycle till cancer diagnosis, by promoting carcinogenesis of spontaneous ovarian granulosa cell tumors or inducing theca-cell ovarian tumors, as animal studies (38) (39) (40) (41) (42) has demonstrated that androgens may be involved in ovarian cancer induction after a long induction period.
In summary, this study is the first prospective epidemiological investigation providing initial direct evidence that elevated androgens, and testosterone in particular, play an important role in the pathogenesis of SCST long before the clinical onset of the disease. Our data suggests that SCST and GCT have distinct hormonal risk profiles, possibly reflecting differences in their pathogenesis. Our study may note a particular need for larger confirmatory investigations on sex steroids and NEOC. 
